Subcutaneous Drug Delivery Devices Market Report Scope & Overview:
Get More Information on Subcutaneous drug delivery devices Market - Request Sample Report
The Subcutaneous Drug Delivery Devices Market was worth USD 30.92 billion in 2023 and is predicted to be worth USD 56.95 billion by 2032, growing at a CAGR of 7.07 % between 2024 and 2032.
The rising prevalence of diabetes and cardiovascular diseases (CVD), along with surging biological drug development, is significantly boosting the demand for advanced minimally invasive Subcutaneous drug delivery devices. According to the International Diabetes Federation (IDF), there will be a 47.8% increase in the number of global diabetes cases from 2017 to year 2045, with major increases occurring in low and middle-income countries. The World Heart Federation notes that diabetics with type 2 diabetes have a higher risk of developing CVD than non-diabetic individuals. The increased purchasing power of the state and advanced healthcare facilities present in California leads to high sales revenues. To address the diabetes surge, companies are focusing on developing prefilled syringes like insulin autoinjectors. Some examples are Biocorp's Mallya device which gained FDA 510(k) clearance and a CE mark in December 2022, throwing open the doors for drug-device combination product innovation. This results in a higher prevalence of cardiovascular diseases and diabetes among the elderly population which makes it more necessary to use a subcutaneous delivery mechanism for drug administration purposes. The American Heart Association predicts that by 2050, cardiovascular disease will affect 15% of the population, up from 11.3% in 2020, with stroke rates expected to double.
Increased prevalence of chronic diseases is driving the market, with changing regulatory approvals impacting competition. Companies such as Insulet Corporation and Ypsomed AG are heavy investments in R&D activities followed by strategic partnerships. Industry and Innovation are Transforming the Health Category with Smart Capabilities for Remote Monitoring, Bio-Compatible Materials and Miniaturized Equipment. For example, the BD Libertas™ Wearable Injector (BD), launched in May 2024 streamlines self-administered subcutaneous injections with automated functions to improve overall patient experience.
Drivers
The growing incidence of chronic conditions such as diabetes, cardiovascular diseases, and autoimmune disorders results in growing demand for efficient drug delivery methods.
Continuous innovations in subcutaneous drug delivery devices, including smart features and improved materials, enhance their effectiveness and appeal.
The increasing elderly population with chronic health conditions boosts the demand for user-friendly and effective drug delivery solutions.
The trend toward self-administration and home-based care supports the growth of devices that allow patients to manage their conditions independently.
The increasing prevalence of chronic diseases such as cardiovascular conditions and diabetes are the important drivers for the growth of the subcutaneous drug delivery devices market. The International Diabetes Federation (IDF) forecasts the total number of diabetic patients worldwide will achieve 1.28 billion by 2050, which illustrates a growth rate of an incredible up to nearly 47% increase from 2017. This expanding patient population highlights an imperative necessity for well-designed and user-friendly subcutaneous drug delivery devices. The high burden of these chronic conditions is further exemplified by the World Heart Federation, which estimates that 17.6 million people die every year from cardiovascular diseases. This increasing incidence results in a greater need for effective drug delivery platforms, specifically to administer treatments that necessitate chronic use. According to the American Diabetes Association, for instance, some 38.38 million Americans suffered from diabetes in 2021 which is a significant segment of the population that are prime candidates for advanced treatment solutions. The increasing number of chronic diseases requires ongoing technical innovations for drug delivery, allowing patients to be satisfied and improve their quality of life.
The growing elderly population is a prominent factor that propels the subcutaneous drug delivery devices Industry. According to the World Economic Forum, 1 in 10 people were aged 80 or older in Japan by 2023. That demographic shift also translates into a greater incidence of NCDs diabetes, COPD and heart failure are all typical examples which are diseases that predominantly affect the elderly. The rising elderly population will result in soaring demand for easier and more efficient drug delivery solutions, as conventional routes often present limitations while managing multifaceted morbidities.
Restraints
The high cost associated with advanced subcutaneous drug delivery devices can limit their accessibility, particularly in low- and middle-income regions.
The complexity of some devices can pose challenges for users, particularly older adults or those with limited technical skills.
One major factor restricting the subcutaneous drug delivery devices market is that it has a high price which comes with advanced devices. The price is not just in the initial purchase of these devices but ongoing costs related to maintenance and consumables. The price of an insulin pump-based a subcutaneous drug delivery device, for example, can cost $4-7k just for the machine itself with add-on costs to cover consumables and supplies.
This high cost can be a barrier to adoption, especially in countries with low and middle-income per head where health budgets are tight. A WHO report in 2023 reveals that nearly round about 40% of diabetics are deprived of diabetes care because of a lack of affordability. Consequently, patients in these regions could not benefit from the latest drug delivery technologies for disease management and treatment. The financial burden associated with these devices can potentially hinder the worldwide adoption, and market growth as well for regions showing low health care expenditure.
By Product
The pen injectors segment held a dominant position in the market on account of their high convenience, easy handling, and efficient enhancement to patient compliance witnessed through a 35% share in revenue generated by it during 2023. The increasing prevalence of chronic diseases, coupled with technological advancements has fuelled the use of pen injectors for insulin delivery in diabetes and other chronic disease management. The consistently high prevalence of breast cancer and continuously shifting trends towards home-based treatments are other value propositions favoring this segment to emerge as the largest market globally. Thus, in February 2023, Phillips-Medisize a Molex company announced the launch of an innovative and market-driven disposable pen injector.
On the other hand, auto-injectors are projected to grow with a significant CAGR during 2024-2032. This supply includes devices for self-administered medicines in areas such as autoimmune diseases, allergies, and hormone deficiencies. Ypsomed reached a long-term agreement with Novo Nordisk in September 2023 to supply autoinjectors for treatments of metabolic conditions. The fact that Novo Nordisk is investing to extend capacity at Ypsomed's facility indicates rising demand in the market. The ADA classification follows on the heels of FDA clearance for interscatter communication-based smart contact lens technology, which can be used to program and monitor intraocular pressure based on glucose levels in persons with diabetes. Novo Nordisk's investment in expanding Ypsomed's production capacity underscores the growing market need. The new autoinjectors, anticipated for Novo's GLP-1 drugs by 2025, highlight the expanding demand in this segment.
By Distribution Channel
The retail pharmacies led the market with more than 45% revenue share in 2023 largely due to easy-access subcutaneous drug delivery devices that are available over-the-counter. It is a convenient procurement point for patients with chronic conditions such as Diabetes who require regular medication. What's more, the personalized care & support provided by pharmacists is effective in increasing patient compliance and driving better treatment outcomes; a factor further underpinning its lead as it remains segment's dominant market position.
On the other hand, the online pharmacies segment is likely to grow at the fastest growth rate of 8.5% during the forecast period. This is driven by increased demand for the convenience of online pharmaceutical purchasing, especially in patients with multiple disorders. Subcutaneous drug delivery devices are delivered to your door via online pharmacies with little or no embarrassment and are available widely. Furthermore, the growing adoption of digital health solutions and attractive offers at competitive prices with detailed information about products are further fuelling this segment. The shift is geared toward a more tech-savvy patient population that expects health care to be delivered in an effective, efficient manner. Online pharmacies will be able to have a larger part of the market as they improve their services and reach.
Need any customization research on subcutaneous drug delivery devices market - Enquiry Now
Regional analysis
North America dominated the subcutaneous drug delivery devices market with more than 43% share of revenue in 2023 due to the presence of a well-established healthcare sector, advanced infrastructure and a higher focus on research & development activities that aid regional growth. The high rates of chronic conditions, such as diabetes, autoimmune disorders and cardiovascular diseases underpin this dominance. In 2021, the American Diabetes Association found that there were already some 38.39 million Americans (approx. 11.58% of the total population) with diabetes implying a need for management tools to help. In North America alone, the US accounts for a considerable share of the market due to the high prevalence of diabetes and prediabetes gaining over 136 million adults with these conditions as per CDC data. Big players including Insulet Corporation, Enable Injections, Amgen BD, and others are innovating New Devices catering to the Rising Demand for Chronic Diseases.
The market is growing in the Asia Pacific region with the fastest CAGR of 8.7% during the forecast period, increasing disposable income, improved healthcare infrastructure, and economic development of countries such as Japan, China, and India. This region claims the highest number of individuals dispatched in the quest for more affordable cures supported by big investments from multinationals. Japan, has a large number of social pensioners (more than 10 percent are expected to be over the age of 80 by 2023). This demographic shift has led to more chronic diseases such as COPD and heart failure, which in turn is increasing demand for patient-centric drug delivery solutions. China is anticipated to witness substantial growth majorly due to a vast aging population, and healthcare reforms. Additionally, India's growth is attributed to favorable regulations and higher healthcare spending while cancer incidence increased with around 1,461427 new cancer cases in 2022.
The Major players in market are Amgen Inc., West Pharmaceutical Services, Inc., Medtronic Plc, Ypsomed AG, Becton, Dickinson and Company, Elcam Medical Group, Novo Nordisk, Gerresheimer AG, Insulet Corporation, , PharmaJet, Halozyme, Inc. Enable Injections, and others in final report.
Recent Developments
Novo Nordisk A/S teamed up with HemoCue to enhance point-of-care diagnostic testing for children with type 1 diabetes in low- and middle-income countries back in February 2024.
Ypsomed came together with ten23 health in April 2024 to market the YpsoDose patch injector. This collaboration will accelerate the progress of developing a user-friendly continuous subcutaneous drug delivering device YpsoDose for better patient convenience. The partnership marries the capabilities of both companies to make this highly advanced injection technology available commercially.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 30.92 Billion |
| Market Size by 2032 | US$ 56.95 Billion |
| CAGR | CAGR of 7.07 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Auto Injectors, Prefilled Syringes, Pen Injectors, Wearable Injectors, Needle-free Injectors) • By Application (Diabetes, Oncology, Fertility) • By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Amgen Inc., West Pharmaceutical Services, Inc., Medtronic Plc, Ypsomed AG, Becton, Dickinson and Company, Elcam Medical Group, Novo Nordisk, Gerresheimer AG, Insulet Corporation, , PharmaJet, Halozyme, Inc. Enable Injections |
| Key Drivers | • The growing incidence of chronic conditions such as diabetes, cardiovascular diseases, and autoimmune disorders results in growing demand for efficient drug delivery methods. • Continuous innovations in subcutaneous drug delivery devices, including smart features and improved materials, enhance their effectiveness and appeal. |
| RESTRAINTS | • The high cost associated with advanced subcutaneous drug delivery devices can limit their accessibility, particularly in low- and middle-income regions. • The complexity of some devices can pose challenges for users, particularly older adults or those with limited technical skills. |
Ans. The projected market size for the Subcutaneous drug delivery devices Market is USD 56.95 billion by 2032.
Ans: The pen injectors product segment dominated the Subcutaneous drug delivery devices Market.
Ans: The North American region dominated the market in 2023, with a 43% share.
Ans. The CAGR of the Subcutaneous drug delivery devices Market is 7.07% During the forecast period of 2024-2032.
Ans: Yes, you can customize the report as per your requirements.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Subcutaneous drug delivery devices Market Segmentation, by Product
7.1 Chapter Overview
7.2 Auto Injectors
7.2.1 Auto Injectors Market Trends Analysis (2020-2032)
7.2.2 Auto Injectors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Prefilled Syringes
7.3.1 Prefilled Syringes Market Trends Analysis (2020-2032)
7.3.2 Prefilled Syringes Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Pen Injectors
7.4.1 Pen Injectors Market Trends Analysis (2020-2032)
7.4.2 Pen Injectors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Wearable Injectors
7.5.1 Wearable Injectors Market Trends Analysis (2020-2032)
7.5.2 Wearable Injectors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Needle-free Injectors
7.6.1 Needle-free Injectors Market Trends Analysis (2020-2032)
7.6.2 Needle-free Injectors Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Subcutaneous drug delivery devices Market Segmentation, by Application
8.1 Chapter Overview
8.2 Diabetes
8.2.1 Diabetes Market Trends Analysis (2020-2032)
8.2.2 Diabetes Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Oncology
8.3.1 Oncology Market Trends Analysis (2020-2032)
8.3.2 Oncology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Fertility
8.4.1 Fertility Market Trends Analysis (2020-2032)
8.4.2 Fertility Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Subcutaneous drug delivery devices Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Retail Pharmacies
9.2.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospital Pharmacies
9.3.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacies
9.4.1 Online Pharmacies Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.4 North America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.5 North America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.6.2 USA Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.6.3 USA Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.7.2 Canada Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.7.3 Canada Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.2.8.2 Mexico Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.6.2 Poland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.7.2 Romania Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.4 Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.6.2 Germany Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.7.2 France Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.7.3 France Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.8.2 UK Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.9.2 Italy Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.10.2 Spain Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.13.2 Austria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.4 Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.6.2 China Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.6.3 China Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.7.2 India Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.7.3 India Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.8.2 Japan Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.8.3 Japan Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.9.2 South Korea Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.10.2 Vietnam Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.11.2 Singapore Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.12.2 Australia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.12.3 Australia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.4 Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.6.2 UAE Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.4 Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.5 Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.4 Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.5 Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.6.2 Brazil Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.7.2 Argentina Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.8.2 Colombia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Subcutaneous drug delivery devices Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 West Pharmaceutical Services, Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Medtronic Plc
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Ypsomed AG
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Becton, Dickinson and Company
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Halozyme, Inc
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Elcam Medical Group
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Novo Nordisk
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Gerresheimer AG
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Insulet Corporation
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Product
Auto Injectors
Prefilled Syringes
Pen Injectors
Wearable Injectors
Needle-free Injectors
By Application
Diabetes
Oncology
Fertility
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Cryoablation Devices Market size will reach $1295.34 Mn by 2032, was valued at $489.53 Mn in 2023 & growing at a CAGR of 10.26% over 2024-2032.
The Urinary Catheters Market size was valued at USD 5.52 billion in 2023 and is estimated to reach USD 8.66 billion by 2031 with a growing CAGR of 5.8% Over the Forecast Period of 2024-2031.
The Clinical Trial Imaging Market Size was valued at USD 1.2 billion in 2023 and is expected to reach USD 2.14 billion by 2031 and grow at a CAGR of 7.5% over the forecast period 2024-2031.
The Patient Access Solutions Market Size was valued at USD 1.96 billion in 2023, and is expected to reach USD 3.90 billion by 2031, and grow at a CAGR of 9% over the forecast period 2024-2031.
The IoT Medical Devices Market Size was valued at USD 41.4 billion in 2023 and is expected to reach USD 503.6 billion by 2032 and grow at a CAGR of 32.0% over the forecast period 2024-2032.
The Bispecific Antibodies Market size was estimated at USD 8.24 billion in 2023 and is expected to reach USD 153.23 billion by 2031 with a growing CAGR of 44.1% during the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
